Vertex Pharmaceuticals Incorporated
DE ˙ XTRA ˙ US92532F1003
368,15 € ↑3,40 (0,93%)
2026-06-04
AKTIENPREIS
SecurityDE:VX1 / Vertex Pharmaceuticals Incorporated
InstitutionBnp Paribas
Latest Disclosed Ownership4,291 shares
Latest Disclosed Value $ 1,916,103
Bnp Paribas reports 39.89% decrease in ownership of VX1 / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - Bnp Paribas filed a 13F-HR form disclosing ownership of 4,291 shares of Vertex Pharmaceuticals Incorporated (DE:VX1) valued at $1,652,464 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 7,139 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -39.89% during the quarter. The current value of the position is $1,579,732 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 4,291 -2,848 -39.89 1,916 -40.79 0.0358
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 7,139 1,798 33.66 3,237 54.76 0.0926
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 5,341 -235 -4.21 2,092 -15.75 0.0631
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 5,576 -258 -4.42 2,482 -12.23 0.0806
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS INC COM EQUITY 92532F100 5,834 -350 -5.66 2,828 13.57 0.1172
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 6,184 531 9.39 2,490 -5.29 0.0148
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 5,653 -282 -4.75 2,629 -5.47 0.1092
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS INC COM Equity 92532F100 5,935 -1,160 -16.35 2,782 -6.21 0.1400
2024-05-02 2024-03-31 13F VERTEX PHARMACEUTICALS INC COM Equities 92532F100 7,095 7,095 2,966 0.1384
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.